Fierce Pharma
AUGUST 20, 2024
Regulators in both the U.S. and Europe have looked into the potential link between suicidal thoughts and Novo Nordisk’s blockbuster semaglutide franchise after reports sounded the alarm last year. | Researchers found that users of Novo's semaglutide who were logged in a WHO database were more likely to report suicidal ideation.
MedCity News
AUGUST 20, 2024
The lack of access to quality healthcare is often cited as the reason for maternal health disparities. But these issues go beyond access, according to Bayo Curry-Winchell, MD, founder of Beyond Clinical Walls and urgent care medical director at St. Mary’s Health Network. The post Maternal Health Crisis: Lack of Access to Care “Doesn’t Paint the Whole Picture,” Expert Says appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 20, 2024
As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. | As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.
MedCity News
AUGUST 20, 2024
In a Phase 3 study, Eli Lilly’s tirzepatide led to a 94% reduction in the risk that obese or overweight prediabetes patients progress to type 2 diabetes. Lilly was already planning to expand use of the blockbuster metabolic disorders drug to sleep apnea and heart failure. The post Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy appeared first on MedCity News.
Fierce Pharma
AUGUST 20, 2024
Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show. | Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.
MedCity News
AUGUST 20, 2024
If enacted, the codes will represent the first major step toward broad-based reimbursement for digital therapeutics, and acknowledgement that CMS recognizes the substantial role new digital solutions can provide. The post Proposed Medicare Codes a Game-Changer for Digital Health appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 20, 2024
Three ways healthcare organizations can benefit from leveraging qualified revenue integrity professionals to enhance CDM technology and drive additional ROI The post Leveraging Experienced Revenue Integrity Professionals to Enhance CDM Technology appeared first on MedCity News.
Fierce Pharma
AUGUST 20, 2024
For years, Teva has been defending itself against allegations that it used illegal Medicare co-pay schemes to fuel sales of its multiple sclerosis drug Copaxone. | The new lawsuit, filed in a Kansas court, comes as Teva defends against similar allegations made by the U.S. government.
pharmaphorum
AUGUST 20, 2024
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese adults with pre-diabetes.There's plenty of evidence to show that prediabetes – a higher-than-normal blood sugar level resulting from a level of insulin resistance that isn't high enough to be considered full-blown diabetes – can be reversed if patients commit to an intensive regimen of dietary restriction
MedCity News
AUGUST 20, 2024
These strategies and practices can significantly shorten the life cycle of claims, leading to quicker resolutions and improved financial outcomes. The post Accelerating Claim Processing: Strategies to Shorten the Life of a Claim appeared first on MedCity News.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
AUGUST 20, 2024
Emergent BioSolutions has agreed to donate 50,000 doses of its mpox vaccine for use in the current outbreak, but an expert has warned supplies are unlikely to meet demand
Pharmaceutical Technology
AUGUST 20, 2024
The top 20 biopharmaceutical companies demonstrated resilience during the second quarter (Q2) of 2024 as global markets and investor optimism improved with anticipation of a potential interest rate cut from the US Federal Reserve.
pharmaphorum
AUGUST 20, 2024
Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of cancer.Copenhagen-based Adcendo is paying what is rumours to be tens of millions of dollars in upfront fees for rights to Multitude's anti-tissue factor (TF) ADC AMT-754 – now renamed ADCE-T02 – outside mainland China, Hong Kong, Macau, and Taiwan.
MedCity News
AUGUST 20, 2024
After several quarters with little to no exit activity in the medtech space, several startups made exits in the second quarter of 2024, according to a new report. The post Public Exits Are Getting More Feasible In The Medtech Space appeared first on MedCity News.
ALULA
AUGUST 20, 2024
Hybrid work continues to impact employees’ preferences, but how does it impact their leaders? In 2021, the World Trend Index reported that 73% of employees wanted flexible remote work options. The latest insights from Gallup show the number dipping only slightly to 60% today. Remote-capable employees are getting what they want , as most are working in a hybrid or exclusively remote arrangement.
pharmaphorum
AUGUST 20, 2024
GSK gets FDA breakthrough status for its B7-H3 directed ADC, licensed from Hansah Pharma in a $1.
PharmaVoice
AUGUST 20, 2024
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
pharmaphorum
AUGUST 20, 2024
Avidity Bio raises $345m from its second big public offering of 2024, after reporting encouraging Duchenne muscular dystrophy data.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
AUGUST 20, 2024
Supplies of Emergent’s smallpox vaccine ACAM2000 will accompany Bavarian Nordic’s vaccine to African countries.
pharmaphorum
AUGUST 20, 2024
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jane Reed, director of life sciences at Linguamatics, an IQVIA company, to discuss some of the major barriers preventing researchers from accessing the data they need to advance drug discovery and development and address safety concerns – and just how AI technologies can assist.
PharmaTimes
AUGUST 20, 2024
The company’s Cell & Gene Therapy Centre can now offer a full range of GMP services
Pharmaceutical Commerce
AUGUST 20, 2024
The latest news for pharma industry insiders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
AUGUST 20, 2024
On July 2024, Colombia's President Gustavo Petro signed Law 2386 of 2024, which declared the pharmaceutical sector as strategic, at least in writing.
Clarify Health
AUGUST 20, 2024
Within healthcare, harnessing data effectively is crucial for any organization striving to deliver exceptional patient care, drive operational efficiency, and remain competitive. Safe to say, the last several years have been extraordinarily difficult for health systems – in 2023 alone, 40% of health systems were not profitable. More than ever, these circumstances underpin the necessity for organizations to leverage the best and most reliable data in order to continue delivering the best care pos
PharmExec
AUGUST 20, 2024
The acquisition, valued at $600 million, is expected to integrate V-Wave into Johnson & Johnson MedTech, which could improve the treatment of heart failure with reduced ejection fraction.
Clarify Health
AUGUST 20, 2024
Within healthcare, harnessing data effectively is crucial for any organization striving to deliver exceptional patient care, drive operational efficiency, and remain competitive. Safe to say, the last several years have been extraordinarily difficult for health systems – in 2023 alone, 40% of health systems were not profitable. More than ever, these circumstances underpin the necessity for organizations to leverage the best and most reliable data in order to continue delivering the best care pos
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
PharmExec
AUGUST 20, 2024
Approval marks the first multitargeted regimen to surpass Tagrisso in efficacy in the first-line treatment of advanced non-small cell lung cancer, according to Johnson & Johnson.
PM360
AUGUST 20, 2024
CHICAGO, Aug. 12, 2024 – Leading healthcare marketer AbelsonTaylor Group has launched a full-service media agency, AT Activate , to provide one-stop, data-driven media strategy, planning, buying and analytics services to ensure that healthcare media campaigns hit their targets and deliver measurable business success for clients. AT Activate will leverage the full capabilities, advanced analytics expertise, and established media network of AbelsonTaylor Group.
PharmExec
AUGUST 20, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
PharmaTech
AUGUST 20, 2024
Genentech will have access to Sangamo’s capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines for certain neurodegenerative diseases.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
351 
Let's personalize your content